The 100 largest Healthcare companies by market cap, with valuation and cash-flow metrics.
| Ticker | Company | Market cap | P/E | FCF yield |
|---|---|---|---|---|
| LLY | Eli Lilly | $1.21T | 42.4 | 0.5% |
| JNJ | Johnson & Johnson | $664.95B | 25.9 | 2.9% |
| ABBV | AbbVie | $514.92B | 22.7 | 3.5% |
| MRK | Merck | $361.73B | 47.0 | 3.4% |
| UNH | UnitedHealth Group | $353.17B | 19.3 | 4.5% |
| NVS | Novartis | $307.00B | 19.0 | 4.8% |
| AZN | AstraZeneca | $289.14B | 38.8 | 3.0% |
| TMO | Thermo Fisher Scientific | $257.42B | 28.1 | 2.4% |
| AMGN | Amgen | $249.05B | 19.9 | 3.2% |
| GILD | Gilead Sciences | $207.00B | — | 4.5% |
| ABT | Abbott Laboratories | $190.39B | 20.4 | 3.9% |
| NVO | Novo Nordisk A/S | $177.74B | 11.0 | 2.4% |
| PFE | Pfizer | $167.52B | 9.6 | 5.4% |
| DHR | Danaher | $161.86B | 27.6 | 3.2% |
| ISRG | Intuitive Surgical | $159.96B | 41.8 | 1.5% |
| VRTX | Vertex Pharmaceuticals | $138.71B | 28.8 | 2.3% |
| MDT | Medtronic | $130.22B | 17.8 | 4.1% |
| BMY | Bristol-Myers Squibb | $127.02B | 10.0 | 10.1% |
| SYK | Stryker | $124.06B | 22.8 | 3.4% |
| MCK | McKesson | $122.48B | 24.9 | 4.1% |
| SNY | Sanofi | $112.71B | 9.1 | 7.0% |
| CVS | CVS Health | $107.28B | 10.1 | 7.3% |
| HCA | HCA Healthcare | $103.40B | 16.5 | 6.5% |
| MRNA | Moderna | $101.48B | — | -2.1% |
| GSK | GSK | $100.88B | 10.6 | 6.2% |
| REGN | Regeneron Pharmaceuticals | $93.55B | 16.4 | 3.8% |
| ELV | Elevance Health | $91.96B | 14.0 | 3.3% |
| CI | Cigna Group | $77.58B | 9.3 | 10.6% |
| TAK | Takeda Pharmaceutical | $67.16B | 42.0 | 6.0% |
| COR | Cencora | $63.65B | 18.6 | 4.9% |
| CAH | Cardinal Health | $62.92B | 23.3 | 7.0% |
| BSX | Boston Scientific | $61.96B | 13.4 | 5.3% |
| EW | Edwards Lifesciences | $58.73B | 34.7 | 2.2% |
| ARGX | argenx | $58.31B | 32.4 | 0.9% |
| BDX | Becton, Dickinson | $57.71B | 16.1 | 4.4% |
| IDXX | IDEXX Laboratories | $53.26B | 45.6 | 1.9% |
| MDLN | Medline | $52.17B | 25.1 | 4.0% |
| HUM | Humana | $52.08B | 32.7 | 0.7% |
| TEVA | Teva Pharmaceutical Industries | $49.72B | 18.0 | 2.3% |
| A | Agilent Technologies | $49.28B | 28.8 | 2.3% |
| VEEV | Veeva Systems | $49.18B | 35.0 | 2.8% |
| ONC | BeOne Medicines | $46.30B | 51.7 | 1.9% |
| WAT | Waters | $44.93B | 31.8 | 2.0% |
| IQV | IQVIA | $44.80B | 21.2 | 4.3% |
| NTRA | Natera | $44.78B | — | 0.2% |
| RVMD | Revolution Medicines | $41.59B | — | -2.5% |
| HLN | Haleon | $40.17B | 21.3 | 7.2% |
| RPRX | Royalty Pharma | $38.70B | 12.7 | 5.0% |
| GEHC | GE HealthCare Technologies | $37.25B | 16.8 | 4.0% |
| BIIB | Biogen | $36.71B | 21.1 | 5.4% |
| ALC | Alcon | $36.23B | 23.0 | 4.3% |
| CNC | Centene | $34.53B | 13.2 | 12.6% |
| MTD | Mettler-Toledo International | $34.51B | 37.2 | 2.4% |
| RMD | ResMed | $33.10B | 20.4 | 3.7% |
| GMAB | Genmab A/S | $32.98B | 38.9 | 3.4% |
| ZTS | Zoetis | $32.81B | 12.0 | 6.5% |
| ILMN | Illumina | $32.23B | 40.6 | 2.8% |
| LH | Labcorp | $29.77B | 20.3 | 3.9% |
| PHG | Koninklijke Philips | $29.67B | 15.2 | 1.9% |
| DXCM | DexCom | $29.62B | 29.7 | 3.4% |
| DGX | Quest Diagnostics | $28.21B | 23.1 | 4.7% |
| ROIV | Roivant Sciences | $28.08B | — | -3.5% |
| WST | West Pharmaceutical Services | $27.85B | 43.5 | 1.6% |
| INSM | Insmed | $25.10B | — | -4.2% |
| STE | STERIS | $24.60B | 23.2 | 3.9% |
| INCY | Incyte | $24.39B | 38.6 | 5.5% |
| UTHR | United Therapeutics | $23.94B | 21.2 | 3.9% |
| VTRS | Viatris | $22.87B | 7.8 | 7.9% |
| THC | Tenet Healthcare | $22.55B | 12.7 | 9.8% |
| BNTX | BioNTech | $21.70B | — | -1.6% |
| ALNY | Alnylam Pharmaceuticals | $20.89B | 7.3 | 2.2% |
| GH | Guardant Health | $20.25B | — | -1.2% |
| ZBH | Zimmer Biomet | $19.98B | 12.4 | 6.8% |
| MEDP | Medpace | $18.27B | 36.2 | 3.5% |
| RVTY | Revvity | $17.31B | 28.0 | 2.8% |
| EXEL | Exelixis | $16.98B | 19.0 | 4.3% |
| ASND | Ascendis Pharma A/S | $16.90B | — | 0.3% |
| NBIX | Neurocrine Biosciences | $16.66B | 16.5 | 4.4% |
| CRL | Charles River Laboratories International | $16.17B | 32.0 | 3.1% |
| SOLV | Solventum | $15.38B | 12.8 | -0.1% |
| ICLR | ICON Public | $15.34B | 18.5 | 5.0% |
| JAZZ | Jazz Pharmaceuticals | $15.07B | 15.8 | 8.0% |
| BBIO | BridgeBio Pharma | $14.47B | — | -3.2% |
| TEM | Tempus AI | $13.87B | — | -1.9% |
| EHC | Encompass Health | $13.50B | 22.4 | 3.1% |
| BTSG | BrightSpring Health Services | $13.36B | 39.3 | 2.7% |
| BAX | Baxter International | $13.34B | 13.3 | 2.4% |
| GKOS | Glaukos | $13.28B | — | -0.3% |
| SMMT | Summit Therapeutics | $13.06B | — | -2.6% |
| SNN | Smith & Nephew | $13.04B | 13.8 | 6.3% |
| ELAN | Elanco Animal Health | $12.86B | 24.3 | 2.2% |
| PEN | Penumbra | $12.58B | 72.5 | 1.4% |
| RDY | Dr. Reddy's Laboratories | $12.43B | 20.4 | 1.5% |
| FMS | Fresenius Medical Care | $12.15B | 10.2 | 14.5% |
| DVA | DaVita | $12.04B | 13.6 | 9.0% |
| COO | Cooper Companies | $11.86B | 13.5 | 3.5% |
| HALO | Halozyme Therapeutics | $11.76B | 17.2 | 2.8% |
| ALGN | Align Technology | $11.70B | 14.7 | 4.1% |
| UHS | Universal Health Services | $11.52B | 8.6 | 6.5% |
| TECH | Bio-Techne | $11.43B | 37.7 | 2.3% |